2197 Stock Overview
A biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Clover Biopharmaceuticals, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.34 |
| 52 Week High | HK$0.58 |
| 52 Week Low | HK$0.20 |
| Beta | 3.49 |
| 1 Month Change | 51.58% |
| 3 Month Change | 19.64% |
| 1 Year Change | -24.72% |
| 3 Year Change | -95.78% |
| 5 Year Change | n/a |
| Change since IPO | -97.42% |
Recent News & Updates
Recent updates
Companies Like Clover Biopharmaceuticals (HKG:2197) Are In A Position To Invest In Growth
Mar 17
Is Clover Biopharmaceuticals (HKG:2197) In A Good Position To Deliver On Growth Plans?
Nov 29Will Clover Biopharmaceuticals (HKG:2197) Spend Its Cash Wisely?
Aug 31We're Hopeful That Clover Biopharmaceuticals (HKG:2197) Will Use Its Cash Wisely
Apr 28Clover Biopharmaceuticals, Ltd. (HKG:2197) Shares Could Be 28% Below Their Intrinsic Value Estimate
Feb 05Shareholder Returns
| 2197 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 37.9% | 11.7% | 3.2% |
| 1Y | -24.7% | 18.9% | 23.6% |
Return vs Industry: 2197 underperformed the Hong Kong Biotechs industry which returned 18.9% over the past year.
Return vs Market: 2197 underperformed the Hong Kong Market which returned 23.6% over the past year.
Price Volatility
| 2197 volatility | |
|---|---|
| 2197 Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in HK Market | 13.9% |
| 10% least volatile stocks in HK Market | 3.1% |
Stable Share Price: 2197 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2197's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 323 | Joshua G. Liang | www.cloverbiopharma.com |
Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China. Its product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza A and B; SCB-219M, a thrombopoietin receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia; and SCB-313, an oncology product candidate for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis. The company is also developing SCB-2023B for COVID-19 treatment; SCB-1019, a product development platform for the creation of protein-based vaccines based on naturally trimerization-dependent targets; and SCB-1001 for rabies treatment.
Clover Biopharmaceuticals, Ltd. Fundamentals Summary
| 2197 fundamental statistics | |
|---|---|
| Market cap | HK$479.91m |
| Earnings (TTM) | -HK$948.28m |
| Revenue (TTM) | HK$30.99m |
14.0x
P/S Ratio-0.5x
P/E RatioIs 2197 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2197 income statement (TTM) | |
|---|---|
| Revenue | CN¥28.90m |
| Cost of Revenue | CN¥475.67m |
| Gross Profit | -CN¥446.77m |
| Other Expenses | CN¥437.51m |
| Earnings | -CN¥884.29m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.68 |
| Gross Margin | -1,546.04% |
| Net Profit Margin | -3,060.02% |
| Debt/Equity Ratio | -25.6% |
How did 2197 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/21 09:55 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Clover Biopharmaceuticals, Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Credit Suisse |
| Yang Huang | Credit Suisse |
| Ziyi Chen | Goldman Sachs |